According to the World Health Organization, heart disease remains the No.1 cause of death in the world. If the trend is allowed to continue, by 2015, an estimated 20 million people will die from cardiovascular disease, mostly from heart attack and stroke. In 2005 alone, 7.6 million people died of heart attack-- the population of Switzerland. Now, about one million Americans suffer from heart attack annually. Of these, about 400,000 die.

After a heart attack, the damaged parts of the organ are gradually filled in with scar tissue, which keeps the heart from functioning at full strength. Then heart attack patients leave the hospital with the uncomfortable knowledge of their heightened likelihood for another attack down the road. It's just a nasty situation.

But with exciting progress like this in regenerative therapies, the statistics may change forever in the near future. The entire ball game may change. The great news?

Re-injected stem cells derived from a patient's own heart muscle are reported to successfully regenerate damaged heart tissue and reduce the size of scars from a prior heart attack.

The researchers explain in a video that doctors "are examining whether treating a patient with their cardiac stem cells can literally reduce the size of the scar and restore health function to the heart after a heart attack."

As reported in The Lancet, the answer is a resounding YES.

17 patients received the therapy about three months after their heart attacks. According to Fox News' John Roberts, Dr. Eduardo Marban "measured an average 50 percent reduction in the size of the scar tissue" from the patients, a year after the therapy.

Let's put this into perspective, shall we? Myocardial infarction means irreversible heart muscle death. Dead muscle tissue then eventually turns into scar tissue. This success is phenomenal. It's like making a gourmet French dinner out of meatloaf leftovers. Or perhaps nothing like that.

"One of the holy grails in medicine has been the use of medicine to achieve regeneration," Marban said. "Patients that were treated not only experience shrinkage of their scars, but also new growth of their heart muscle, which is very exciting."

What was the process like? A catheter was first inserted into the diseased hearts to take a small biopsy of muscle. The tissue was then manipulated into producing stem cells. "After a few weeks of marinating in culture, researchers had enough stem cells to re-inject them into the patients' hearts," Roberts reports. "Over the course of a year, the stem cells took root in cardiac tissue, encouraging the heart to create new muscle and blood vessels. In other words, the heart actually began to mend itself."

"Patients that were treated not only experienced shrinkage in their scars, but also new growth of their heart muscle, which is very exciting."

Marban told Roberts, "We've achieved what we have achieved using adult stem cells - in this case - actually specifically from a patient's own heart back into the same patient. There's no ethical issues with that - there's no destruction of embryos." In addition because the stems are the patient's own, "There's no reason to worry about immune rejection," Marban explained.

"If we can do that in the heart, I don't see any reason, conceptually, why we couldn't do it in kidneys for example, or pancreas or other organs that have very limited regenerative capacity," Marban said.

Interestingly, it appears that the stem cells themselves may not have turned into cardiac muscle, "but rather they stimulated the heart to produce new muscle cells," Roberts reported.

Marban told Roberts that the applications could go well beyond diseased hearts.

"As Dr. Marban notes, there is no reason adult stem cells couldn't be used to repair other organs as well," Prentice said. " Besides acute and chronic heart damage as well as angina, studies have already shown initial success using adult stem cells to treat a myriad of conditions, including spinal cord injury, stroke, juvenile diabetes, multiple sclerosis, sickle cell anemia, and dozens more."

References:

Makkar, Raj R., Rachel R. Smith, Ke Cheng, Konstantinos Malliaras, Louise EJ Thomson, and Daniel Berman. "Intracoronary Cardiosphere-derived Cells for Heart Regeneration after Myocardial Infarction (CADUCEUS): A Prospective, Randomised Phase 1 Trial." The Lancet. Elsevier Limited, 14 Feb. 2012. Web. 17 Feb. 2012. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60195-0/abstract.

Excellent news from Organovo! Today, February 14, 2012 in San Diego, Organovo Holdings, Inc. ("Organovo") announced the successful merger with Organovo, Inc. (the "Merger"), a company focused on developing the three-dimensional bioprinting technology for medical research and applications. Organovo closed a private placement of approximately $6.5 million to advance its bioprinting platform.

"Organovo's advanced bioprinting platform can replicate essential biology for research, drug discovery and development and, eventually, for therapeutic applications," stated Keith Murphy, chief executive officer of Organovo. "We have found success in achieving early revenue through strategic collaborations, and this funding will allow us to extend the reach and uses of 3D bioprinting through growth and innovation in the coming years."

We're downright beaming here at Methuselah Foundation, for this is yet another buoyant step towards accomplishing the vision of New Organ.

"Their $6.5 million in additional capital will go a long way toward making new parts for aging bodies a desirable and commonplace outcome. Thanks to all of you who made signal contributions to this ongoing success," said David Gobel, founder of Methuselah Foundation.

References:

"Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications." Money.msn.com. Microsoft, 14 Feb. 2012. Web. 14 Feb. 2012.
http://money.msn.com/business-news/article.aspx?feed=PR&Date=20120214&ID=14791316.

"Surgery was the last resort to save her life and Alannah spent more than a year on a waiting list for the organs," said Dr. Heung Bae Kim, lead surgeon for the procedure at Children's Hospital Boston.

The organs needed? A new stomach, liver, spleen, small intestine, pancreas and an esophageal section to replace the ones being choked by the gigantic tumor. It may be the first ever transplant of an esophagus and the largest number of organs simultaneously transplanted in one human being in New England.

Doctors told the family that there was a 50 percent chance little Alannah would not survive the operation. Without the transplants, she had no chance whatsoever.

The 14-hour procedure occurred in October with the team of doctors preparing to remove the grown and the organs in one fell swoop, replacing them with organs transplanted in one tangled piece from another child of similar size. It was a difficult process involving severe blood loss.

"It's probably one of the most extensive tumor removals ever done," the surgeon said.

The surgery was a success, though Alannah spent three months at the hospital battling infection after infection and complications from the surgery. Finally, she came home this past Wednesday with her grandparents in Hollis about 20 miles west of Portland.

Alannah's immunosuppressant therapy involves nine medications each day, some two, three or four times. Her grandparents methodically and precisely measure everything that comes out of her body. Her blood sugar is regularly checked. An ostomy pouch and feeding tube are attached to her for nutrition as she gradually accustoms herself to eating again.

Because of her weakened immune system, she can't be subjected to environments with large numbers of people such as school, church or the mall. Because of this, a tutor comes to the house 20 hours a week for her education. Raw vegetables and fruit can't be given to her unless they are thick skinned due to concern for germs. She'll never be able to swim in a lake because of the bacteria. Her grandparents, the Skolases installed ultraviolet lights in their heating ducts to kill mold, mildew and bacteria that might sicken Alannah and put her at risk.

"There is a risk that she'll need another transplant down the road. And if there were any tumor cells left behind, there is a risk it could come back," Dr Kim warned, according to ABC News. Alannah will also need to take anti-rejection drugs for the rest of her life.

"Don't even ask," she says when the topic of medical costs comes up. Her grandparents' hand-crafted furniture business has suffered with Debi Skolas devoting her time to Alannah's care. The couple was forced to dip into their retirement to make ends meet. Their friends organized a fundraiser to help offset the medical costs.

But more than anything, the family is grateful for the girl's second chance at life. Alannah is full of spunk and bright-eyed as she scampers around her family's farmhouse. She is still able to sled, make a snowman, and scrapbook.

Imagine a world where Alannah and her grandparents wouldn't have to endure an excruciating year on a wait list for multiple organs. She would have organs generated from her own cells, with a much-lowered risk of infections and complications post-surgery. She wouldn't have to take so many anti-rejection pills a day that suppress her immune system and force her to stay away from school or any environment with lots of people. She would be able to eat the fruits and vegetables she wanted. She would be able to live a much more normal childhood. Her grandparents would not have to dip into their retirement fund just to make ends meet.

That world is the vision of New Organ. With your help and support, we can get there together to save lives and prolong health.

Reference:

Daily Mail Reporter. "Ground-breaking Multi-organ Transplant Saves Girl, 9, after 'monster' Tumour Devours SIX of Her Organs" Mail Online. Associated Newspapers Ltd, 3 Feb. 2012. Web. 3 Feb. 2012.
http://www.dailymail.co.uk/news/article-2095169/Ground-breaking-organ-transplant-saves-Alannah-Shevenell-9-monster-tumour.html.

Join Science magazine for a live chat on anti-aging research, Thursday, January 26 at 3 pm EST. We'll chat with experts Aubrey de Grey and S. Jay Olshansky on the science of aging. They'll answer your questions on a variety of topics, including whether human lifespan will continue to increase, what impact antiaging research could have on global demographics, and what the latest research says about what you can do to combat the ill effects of growing older.

For the first time in human history, cardiac stem cells were used to repair the severely damaged hearts of 16 patients in a trial conducted by researchers from the University of Louisville in the US. "It could offer an entirely new option and a potential cure for patients who are now dying from heart failure," said study author Dr. Roberto Bolli, director of cardiology at the University of Louisville in Kentucky. "The results are striking. While we do not yet know why the improvement occurs, we have no doubt now that ejection fraction increased and scarring increased."

The ejection fraction or "pumping efficiency" of the hearts of eight patients had improved by more than a whopping 12%. These results tripled the 4% improvement the researchers were expecting to see.

"If these results hold up in future studies, I believe this could be the biggest revolution in cardiovascular medicine in my lifetime, " said an impressed Professor Bolli.

The "Schipio" trial included a total of 23 patients, all of whom suffered heart failure due to a previous heart attack. Seven of these received standard care while the other sixteen were assigned to stem cell therapy. The groundbreaking treatment involved extracting cardiac stem cells (CSCs) from patients during bypass surgery. CSCs are self-renewing cells that rebuild hearts and arteries. After a purification process and a period of growth in the laboratory, the cardiac stem cells are then injected back into damaged regions of the patient's hearts four months later. A million of these CSCs were injected into each patient via a balloon catheter, an expandable device used to open up arteries.

Interestingly, this small Phase I study was primarily designed to assess safety rather than effectiveness of the new, cutting-edge treatment. At the start of the study, the patients had an average left ventricular ejection fraction (LVEF) of 40% or lower. Normal LVEF is 50% or higher. Over a period of 4 months, patients who received the treatment saw an 8.5% improvement in LVEF, increasing to 12.3% after one year. LVEF did not change in the seven patients of the "control" group who did not undergo the cardiac stem cell therapy. MRI scans conducted on number of patients revealed that cardiac scarring had been reduced.

"Michael Jones, our first patient, could barely walk 30 feet [before treatment]," Dr. John H. Loughran said. "I saw him this morning. He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week. It is stories like that that makes these results really encouraging."

These findings are published in the online edition of The Lancet medical journal and will be presented at the American Heart Association's Scientific Sessions meeting in Orlando, Florida. Now, Professor Bolli and his team intend on applying for funding a much bigger, multi-centre Phase II trial.

Professor Gerd Heusch from the University School of Medicine in Essen, Germany commented on the study in The Lancet: "The results from Scipio raise new optimism because the study is based on rigorous quality standards and the reported benefits are of an unexpected magnitude... we will have to see whether the further data will meet the promises of the present study. More patients will need to be followed up over a longer period."

Reference:

"Stem Cell Test Is 'biggest Breakthrough in Treating Heart Attacks for a Generation'" The Telegraph. Telegraph Media Group Limited, 14 Nov. 2011. Web. 14 Nov. 2011.
http://www.telegraph.co.uk/health/healthnews/8889031/Stem-cell-test-is-biggest-breakthrough-in-treating-heart-attacks-for-a-generation.html.

The pituitary gland is a pea-sized endocrine gland at the base of the brain that secretes hormones like Human Growth Hormone (HGH) and thyroid stimulating hormone (TSH) that play key roles in human growth, pregnancy, blood pressure, and thyroid function. It's especially crucial during early development, so armed with the ability to simulate the formation of the pituitary gland could help researchers better understand how these developmental processes function. Hormone disorders result from inadequate release of certain hormones like these by the pituitary gland. Growth disorders such as gigantism, vision problems, and even blindness are also associated with disruptions in the pituitary.

This study, published in this week's issue of Nature, is a crucial step forward in medical science's ability to bioengineer complex organs for human transplantation.

Using a three dimensional culture, the team placed the mouse stem cells in a manner that mimics the way a pituitary gland naturally grows in the embryo. The gland is naturally made up of two different tissue types in the brain. The culture in the study was set up so that these two tissues would come together as they do in the brain.

Rathke's pouch - a fold of tissue - formed naturally and grew into the pituitary gland after about two weeks. Prior to this, the researchers only had a vague sense of the signaling factors necessary to form a pituitary gland, but after trial and error, the winning combination involved two main steps, requiring the addition of two growth factors and a drug called "sonic hedgehog" to stimulate a developmental protein. Then, the researchers tested the functionality of their synthesized organs by transplanting the tissue into mice with pituitary dysfunction. The transplants were a success! Levels of glucocorticoid hormones in the blood and behavioral symptoms such as lethargy were stabilized. The mice's hormone levels soon returned to normal.

"This is just an initial step toward generating viable, transplantable human organs, but it's both an elegant and illuminating study," says Michael G. Rosenfeld, a neural stem-cell expert at the University of California, San Diego.

Next, Sasai and colleagues will be attempting the experiment with human stem cells. Sasai suspects it will take them another three years to synthesize human pituitary tissue and perfecting the transplantation methods in animals might take another few years. Still, researchers in the stem-cell field and biomedical researchers on the whole are impressed with what Sasai's team has accomplished. Yet another small victory aimed for the big win!




Reference:

Westly, Erica. "Researchers Create a Pituitary Gland from Scratch." Technology Review. MIT Technology Review, 9 Nov. 2011. Web. 11 Nov. 2011. http://www.technologyreview.com/biomedicine/39108/?p1=A1.

It's common knowledge in the biomedical industry that mice have the ability to regenerate and even expand the capacity of one lung if the other is missing--this study identifies the specific molecular triggers behind this adaptive process. The researchers believe these findings are quite relevant to human beings.

Dr. Shahin Rafii, the Arthur B. Belfer Professor of Genetic Medicine and co-director of the Ansari Stem Cell Institute at Weill Cornell Medical College and this study's lead investigator said "Several adult human organs have the potential upon injury to regenerate to a degree, and while we can readily monitor the pathways involved in the regeneration of liver and bone marrow, it is much more cumbersome to study the regeneration of other adult organs, such as the lung and heart."

"It is speculated, but not proven, that humans have the potential to regenerate their lung aveoli until they can't anymore, due to smoking, cancer, or other extensive chronic damage," says Dr. Rafii, who is also an investigator at the Howard Hughes Medical Institute. "Our hope is to take these findings into the clinic and see if we can induce lung regeneration in patients who need it, such as those with chronic obstructive pulmonary disease (COPD)."

Dr. Rafii and his colleagues previously uncovered growth factors that control regeneration in the liver and bone marrow. In both cases, they found that endothelial cells produce the key inductive growth factors, described as "angiocrine factors". The current lung study revealed the same phenomenon: Blood vessel cells in the lungs jump-start alveoli regeneration. "Blood vessels are not just the inert plumbing that carries blood. They actively instruct organ regeneration," says Dr. Rafii. "This is a critical finding. Each organ uses different growth factors within its local vascular system to promote regeneration."

In the study, the left lungs of mice were removed for Dr. Bi-Sen Ding to examine the biochemical process of the remaining lung's regeneration. According to a prior investigation by Dr. Crystal, once the left lungs were removed, the right lungs regenerated by 80%. It replaced the majority of the lost alveoli. They discovered that when the left lung is removed, receptors on endothelial cells in the lung that respond to basic fibroblast growth factor and vascular endothelial growth factor is triggered.

Research lead Dr. Shafin Rafii explained: "Several adult human organs have the potential upon injury to regenerate to a degree, and while we can readily monitor the pathways involved in the regeneration of liver and bone marrow, it is much more cumbersome to study the regeneration of other adult organs, such as the lung and heart [...]"

Co-author Dr. Ronald G. Crystal said "There is no effective therapy for patients diagnosed with COPD. Based on this study, I envision a day when patients with COPDD and other chronic lung diseases may benefit from treatment with factors derived from lung blood vessels that induce lung regeneration."

Reference:

Rattue, Grace. "Lung Regeneration May Be A Reality Soon." Medical News Today. Medical News Today, 1 Nov. 2011. Web. 2 Nov. 2011. http://www.medicalnewstoday.com/articles/236928.php.

At 60 years of age, Rosenbaum is but one of 46 people arrested in 2009 in a massive federal corruption probe dubbed "Operation Big Rig" that ensnared dozens of officials, politicians, community and religious leaders involved in organ sales, money laundering, and political corruption over an investigative period of 10 years.

From January 2006 to February 2009, Rosenbaum conspired to obtain kidneys from paid donors in exchange for payments of $120,000, $150,000 and $140,000 from three recipients of the organs.

"Rosenbaum admitted he was not new to the human kidney business when he was caught brokering what he thought was a black-market deal," U.S. Attorney Paul Fishman said in a release.

"A black market in human organs is not only a grave threat to public health, it reserves lifesaving treatment for those who can best afford it at the expense of those who cannot [...] We will not tolerate such an affront to human dignity."

Rosenbaum faces up to 20 years in prison when he's sentenced February 2. He agreed to forfeit $420,000 he received in connection with the three transplants and admitted that he invented cover stories and fictitious relationships between donors and recipients so doctors wouldn't know a kidney was being sold.

His black market involvement was exposed with the help of Solomon Dwek, a cooperating criminal defendant who helped prosecutors develop charges against defendants in the "Operation Big Rig" case. Posed as an employee of Dwek and claiming that her uncle needed a transplant, an undercover agent met with Rosenbaum in mid-February 2008. He told them that it was illegal to buy and sell organs but that he had been "doing this a long time" and explained that he would help the recipient and donor concoct a false story to support the appearance of a legitimate donation, Fishman said. Rosenbaum also claimed he would be in charge of "babysitting" the donor after the person arrived from overseas.

"I am what you call a matchmaker," he told the snitch. "I've never had a failure."

During Thursday's plea, Rosenbaum admitted that he typically located Israelis who were willing to be paid for giving up their kidneys and that he was responsible for travel arrangements for the donor to the United States along with their accomodations pre- and post-operation. He arranged for blood samples and helped each paid donor and recipient fabricate stories to fool hospital staff. His lawyers noted that the surgeries took place in "prestigious American hospitals and were performed by experienced and expert" surgeons. He remains free on bail and under house arrest pending sentencing scheduled for February 2, 2012.

Methuselah Foundation's New Organ Prize not only serves to catalyze progress in tissue and organ regeneration but it also aims to make the crimes of the black market a thing of the past. In a future where an individual in need of an organ can have one made with their own cells, the market for organs exploited from the disadvantaged and weak will eventually shrink and disappear altogether.

We at Methuselah Foundation echo the words of Attorney Fishman: "We will not tolerate such an affront to human dignity."

Photo Credit: Tony Kurdzuk | The Star-Ledger

"Our study indicates that getting older does not necessarily mean that the immune system gets weaker, as many of us assumed," says lead investigator Abbe N. de Vallejo, Ph.D., associate professor of pediatrics and immunology at University of Pittsburgh School of Medicine. "The immune system is dynamic, and the changes it undergoes over time very much influence function."

Previous studies showed that immune cells called T-cells become more like natural killer (NK) cells, which typically targets virus-infected cell and tumor cells. For this new study, the team collected blood samples from a body of 140 participants who had been followed in the Cardiovascular Health Study for nearly 20 years and were 78-94 years old. Only two were younger than 82--the average age of the group was 86. The researchers gathered information about the participants' health and function, medical history, hospitalizations, self-rated health, and cognitive and physical function assessments via standardized tests.

A closer look at the new study revealed that those who were most physically and cognitively resilient had a dominant pattern of stimulatory NK receptors on the surface of the T-cell. These unusual T-cells can be activated directly through these NK receptors in a manner independent of the conventional ones. The functionally resilient elders also have a distinct profile of blood proteins called cytokines that reflect an immune-enhancing environment.

The group that showed mild health impairment had a dominant pattern of inhibitory NK receptors on their T-cells, with a cytokine profile indicating a pro-inflammatory environment. Both of these immunologic features might suggest greater susceptibility to illness.

"These findings indicate that there is remodeling or adaptation of the immune system as we age that can be either protective or detrimental," Dr. de Vallejo said. "Now we have an immunological fingerprint that can identify individuals who are more likely to stay physically and cognitively well."

References:

Abbe N. Vallejo, David L. Hamel, Robert G. Mueller, Diane G. Ives, Joshua J. Michel, Robert M. Boudreau, Anne B. Newman. NK-Like T Cells and Plasma Cytokines, but Not Anti-Viral Serology, Define Immune Fingerprints of Resilience and Mild Disability in Exceptional Aging. PLoS ONE, 2011; 6 (10): e26558 DOI: 10.1371/journal.pone.0026558

"We are at the cusp of a revolution in medicine and biotechnology that will radically increase not just our life spans but also, and more importantly, our health spans. That is, we will live longer and with a higher quality of life. [We] will examine the fascinating new technologies that will allow doctors to repair or replace worn-out body parts, re-engineer our bodies, and take preventative measures that will radically lengthen our lives." -Sonia Arrison, 100+ Chapter 2: How Science and Technology Will Increase Life Span

With her new book 100 Plus, Sonia Arrison introduces us to the people and the innovations that are transforming our lives while bringing to the fore a very comprehensive picture of how life-extending discoveries will impact our personal, social, and economic spheres. After a decade of research and writing experience on the breakthrough advances in science and biotechnology, Arrison's wide-angle approach to healthy life extension is both sparklingly informative and thought-provoking.

What will your life look like after reaching your 100th year? Will over-population be a major issue? How will living longer and with more vigor affect your family life, your personal belief system, even your finances? Her work is a fantastic attempt in addressing these questions.

Peter Thiel graces 100 Plus with the following words in his foreward:
"Arrison's book begins with a history of the many great men and women of the past who sought human longevity. She surveys he current generation of scientists and technologists who promise to usher in a new era, demonstrating that aging is a foe that can be hobbled and potentially even beaten. From here Arrison goes to the heart of things by directly confronting opposition to longer and healthier lives and outlining the extraordinary economic, social, and cultural changes that will happen as the world wakes up from history..."

The Methuselah Foundation team is voraciously reading 100 Plus with growing excitement for Arrison's well-informed candor and refreshing perspective on the advances of healthy life extension technologies that cover a wide range of angles.

And as if you needed more reason to go read this book as soon as you can get your hands on it, CEO Dave Gobel had this to say about it from his Amazon review:

"The best thing about 100+ is that it documents the increases in healthy longevity that are already happening right now. Refreshingly, it treats widely held cultural and religious values with legitimate respect, without resorting to the typical elitist/dismissive tone others have taken. 100+ carefully covers new ground on topics that I've not seen covered in detail before - such as how longevity will affect the future of childbearing and the family - based on little known trends and science happening right now. This book is also the best survey of the field of life extension to date, giving useful and actionable insights on such topics as population growth, the environment, economics, medical trials and advances in biotech without burdening the reader with red-herring issues like immortality or demonizing the "opposition". The book is an easy and compelling read and even though I've read extensively on the subject, each page of 100+ offers up new facts with real value - no filler or arm waving here! Highly recommended."

Now how's that for a review? Pick it up, read it, think about it, and tell us how it's affected the way you think about living to see a healthy 100... and beyond!

Reference:

Arrison, Sonia. 100 Plus. New York: Basic, 2011. Print.

Our friend and scientific advisory board member Anthony Atala of the Wake Forest University for Medicine discussed the advances of regenerative medicine in the fourth installment of The University of Rhode Island's Honors Colloquium. The lecture began with a progress report for the new field of regenerative medicine and, reminding the audience that it was only in a few decades ago in 1954 that surgeons transplanted an organ into a human for the first time in history, it's astonishing that as 2012 quickly approaches, medical science has progressed to allow organs such as kidneys, uteruses, bladders, urethras, and even the skin to regrow.

"Is this science fiction?" Atala asks. "Not really. We see it in biology all the time."

He outlined the process a surgeon goes through to regenerate an organ--the easiest organs being flat, such as the skin. For the larger, tubular organs such as the kidney and liver, that happens to be a different, much more difficult ball game.

For skin regeneration, the surgeon simply extracts a bit of cells the size of less than half a postage stamp from the patient. Then, after being mixed with a solution to keep the cells alive, the cells are then sprayed back onto the patient. Should the patient be immobile, he would be scanned by a machine and his cells delivered to a bio-printer. The printer would produce a sticky sheet of gel cells to be administered to the patient to help regenerate his skin.

Nearing the end of his presentation, Atala played a short clip of an interview with former patient Luke M., whose surgery was performed 10 years ago. A new bladder was engineered for him out of his own cells. Prior to the operation, he said he was faced with a lifetime of dialysis. He could barely get out of bed, constantly missed school, and couldn't play basketball with his friends without feeling faint.

"After surgery, I was able to do more things, like wrestle in high school," said Luke, proudly. "I even became captain of the team. Because they used my own cells to build this bladder, I got it for life. So I'm all set."

Atala reminded the audience how 50 years ago, the iron lung was thought to be revolutionary technology. Now, we look back on it and think "Boy, wasn't that primitive?" The goal of medical science is to keep pushing forward and breaking boundaries, he said, so that in the next 50 years, people can look back on his technology and find it primitive as well.

"My goal tonight was to make this look easy to you," he stated. "But I assure you, the work we do is anything but easy. We still have many challenges ahead, but the promise this field holds is to try and make our patients better."

Reference:

Delande, Kimberly. "Colloquium Speaker Addresses Future of Organ Regeneration through Technology." The Good 5¢ Cigar. College Media Network, 5 Oct. 2011. Web. 6 Oct. 2011.
http://www.ramcigar.com/colloquium-speaker-addresses-future-of-organ-regeneration-through-technology-1.2630806#.ToyEoJxZhG8.

The research team, led by Dr. Carl June, removed a billion of William's T-cells (white blood cells that fight viruses and tumors) and engineered them with new genes that reprogram the cells to attack his cancer. A disabled form of H.I.V. -1, the virus that causes AIDS, was employed to transport cancer-fighting genes into the patient's own T-cells. In essence, the team trained Ludwig's own immune system to kill cancer cells. The process is detailed in The New England Journal of Medicine as well as in Science Translational Medicine.

There were no reactions at first but after 10 days, he shook with chills, his temperature skyrocketed while his blood pressure plummeted--William had so rapidly become ill that the doctors moved him into intensive care, warning him that he might die. Fearing the worst, his family gathered at the hospital.

Fast forward a few weeks later. No fever. No leukemia.

All traces of leukemia vanished. No leukemic cells were to be found in his blood or bone marrow; his CT scan was clean. The doctors calculate that the treatment destroyed up to two pounds of cancer cells. One year later, and William is still in complete remission. Before the treatment, there were days when he could barely get out of bed. Now he revels on the green of gulf and works on his yard.

"I have my life back," says William.

"It's great work," said Dr. Walter J. Urba of the Providence Cancer Center and Earle A. Chiles Research Institute in Portland, Ore. He called the patients' recoveries remarkable, exciting and significant. "I feel very positive about this new technology. Conceptually, it's very, very big."

Though Ludwig's doctors do not claim that he is cured, as it is too soon to tell - the research has far to go and the treatment is still experimental and unavailable outside of clinical studies - the treatment has obviously helped Ludwig tremendously. This may be a turning point in the long struggle to develop effective gene therapies to combat cancer. And not just for leukemia--other cancers may also be vulnerable to this breakthrough approach.

Two other chronic lymphocytic leukemia patients were also treated in the experiment; one had a partial remission--his disease lessened but did not completely go away. Another, like William, experienced complete remission. All three were at an advanced stage of the disease, ran out of chemotherapy options, and were not candidates for bone-marrow transplantation.

Dr. Carl June said the results stunned even him and his colleagues, Dr. David L. Porter, Bruce Levine and Michael Kalos. Of course they had hoped to see some benefit of the experimentation, but had not dreamed of seeing complete, prolonged remissions in the patients. When Mr. Ludwig began running fevers, the doctors did not initially realize that it was a sign that his T-cells were furiously battling with his leukemia.

Dr. Walter J. Urba said he thinks the approach would ultimately be used against other types of cancer along with leukemia and lymphoma though he cautions that "For patients today, we're not there yet." And he added the usual scientific caveat: To be considered valid, the results must be repeated in more patients, and by other research teams.

But what profound hope we have for this to be validated!

When Ludwig entered the trial, Dr. June said that he was "almost dead". The trial was Phase 1, meaning that the main goal was to find out if the treatment was safe, and if so, at what doses. Ludwig thought that if the trial study could give him six months to a year, it would be worth it, but even if it didn't help him personally, he felt that it would still be worth helping the study.

"I feel wonderful," Mr. Ludwig said in an interview. "I walked 18 holes on the golf course this morning."

William Ludwig was tremendously week before the study, suffering repeated bouts of pneumonia and wasting away. Now, he is full of energy. He has gained 40 pounds. He and his wife bought an R.V., in which they travel with their grandson and nephew.

"I feel normal, like I did 10 years before I was diagnosed," Mr. Ludwig said. "This clinical trial saved my life."

Reference:

Grady, Denise. "An Immune System Trained to Kill Cancer." The New York Times | Health. The New York Times Company, 12 Sept. 2011. Web. 14 Sept. 2011.
http://www.nytimes.com/2011/09/13/health/13gene.html?_r=2&pagewanted=1&ref=health&src=me.

The hippocampus, an important sea-horse shaped component of the brain that plays a role in memory, spatial memory, and navigation, loses function and ceases to produce new neurons as it ages. Though this deterioration can be partially reversed when animals regularly exercise thereby stimulating circulation and releasing chemicals and metabolites into the blood, Tony Wyss-Coray of Stanford University School of Medicine wondered if there was a blood-borne element that might contribute to these changes.

Published in August 31, 2011 in Nature, his study implies that it may be possible to change some of the aging symptoms of the brain by altering the levels of immune factors in the blood.

By stitching the flank of a young mouse to the flank of an old one, Wyss-Coray and colleagues formed a conjoined-twin effect, allowing the blood of both mice to mingle. They found that the young animals showed a decline in neurogenesis while the old ones showed new growth as compared to young and old stitched to partners of similar age.

"There seemed to be rejuvenation in the old brain," said Wyss-Coray.

So the researchers extracted only blood plasma devoid of the cells of old mice and injected into the young mice. They saw a similar decline in neurogenesis. It appeared as though an extracellular blood protein was responsible. These mice were then administered a battery of memory tests and mazes. The mice with old blood plasma did not form as robust memories and did not remember the solution to a maze as well as normal young mice--similar impairments found in old mice.

In order to identify the element in the plasma that caused this effect, comparisons were made on the concentrations of blood proteins in the conjoined animal; of six candidate proteins whose levels that changed after the mice were stitched together, CCL11 or eotaxin, a chemokine, demonstrated the most significant change.

"The factor [CCL11] is a surprising character," said Richard Ransohoff from the Cleveland Clinic Lerner College of Medicine. "It's a chemokine that has zero prior neurobiology," he added. Known only for its role in attracting eosinophils or immune cells that play a major role in allergy and asthma, when the researchers injected this chemokine into young mice, a decrease in new neuron formation was observed. This effect was then reversed with an injection of a CCL11-blocking antibody! Observing too how CCL11 fluctuates with age, Wyss-Coray and researchers saw that its blood-levels elevated in mice and in humans with age.

Wyss-Coray agrees that this study opens a floodgate of new questions. But he's encouraged by the possibilities. For example, "if we could rejuvenate or maintain the brain in general," he said, it might delay some of the detrimental effects that cause dementia or Alzheimer's.

References:

S. A. Villeda et al., "The ageing systemic milieu negatively regulates neurogenesis and cognitive function," Nature, 477:90-96, doi:10.1038/nature10357, 2011.

We're all interested in living a healthy, long life. For those of us who really mean it, our lifestyle reflects the discipline, restraint, and healthy moderation we think it takes to achieve a vibrant 100 years of life (at least). If you fit that category, reading things like "People who live to 95 or older are no more virtuous than the rest of us in terms of their diet, exercise routine or smoking and drinking habits" may be a bit of an irritation. Yes, you did just read that and we did just quote from a study conducted by researchers of Albert Einstein College of Medicine of Yeshiva University published yesterday, August 3, 2011 in the online edition of Journal of American Geriatrics Society entitled "Lifestyle Factors of People with Exceptional Longevity". Feeling a little grumpy? Bear with me.

The age-old debate between Nature and Nurture rages on in the field of healthy life extension research-- you can guess which side this study seems to lean more towards. "Nature" in this case comes in the form of protective longevity genes while "nurture" represents lifestyle behaviors and habits. This study, involving a few hundred centenarians, suggests that one's genes may play more of an important role in living an exceptionally long life than one's way of living.

The centenarians indulged in smoking and drinking just as much as their shorter-lived contemporaries. Their diets followed the same vein as others in the general population and they were just as likely to be overweight, perhaps even exercising less than the average person. What gives?

Senior author of the study, Nir Barzilai, M.D., the Ingeborg and Ira Leon Rennert Chair of Aging Research and Director of the Institute for Aging Research at Einstein, together with his colleagues, interviewed 477 independent Ashkenazi Jews aged 95 or older, a group more genetically homogenous than other populations. In this manner, the identification of genetic differences contributing to life span would be simplified. This population was questioned about current habits as well as their lifestyle in earlier years.

Now these researchers were intent on peering into the mystery of longevity through wide lenses--data collected in the 1970s were used to compare the long-lived group with another group of some 3,000 individuals from the general population born around the same time but generally didn't get to make it 95 years of age.

To put it plainly: What they found was that people who lived to 95+ did not seem to have healthier lifestyles than those who died younger. Check out these numbers: 43% male centenarians reported exercising regularly at moderate intensity compared with 57% of men of the other group. Almost 30% of the long-lived females were smokers, a bit higher than the 26% in the comparison population who smoked. With the men, that percentage was significantly higher at 60% of the centenarian group compared to the 74% of their shorter-lived counterparts. About 24% of the men in the older group drank alcohol on a daily basis whereas 22% made that a habit from the younger group.

However, men and women from both groups were just as likely to be overweight. But there was one difference. Centenarians were less likely to be obese with only 4.5% of men in the older group compared to the 12% of the other male subjects. A similar pattern was found among women. When asked why they believed they had lived so long, most did not attribute their advanced age to lifestyle habits. 20% believed that physical activity played a role, 19% claimed a positive attitude, 12% to a busy or active life, 15% for less smoking and drinking, 8% believed it was good luck, and 6% attributed their longevity to religion or spirituality.

One finding that came as no surprise from the study was that about a third of the centenarians reported having many long-lived family members and relatives--previous studies of Ashkenazi Jews have helped locate a gene variant in the population that causes significantly elevated levels of HDL or "good" cholesterol in the centenarians that appeared to confer resistance Alzheimer's and heart disease. For those of us who can't claim the gene variant, there is potential good news, Dr. Barzilai says. There is a drug currently being developed that has the same effect on HDL as that particular gene.

"In previous studies of our centenarians, we've identified gene variants that exert particular physiology effects, such as causing significantly elevated levels of HDL or 'good' cholesterol," said Dr. Barzilai, who is also professor of medicine and of genetics at Einstein. "This study suggests that centenarians may possess additional longevity genes that help to buffer them against the harmful effects of an unhealthy lifestyle...We're identifying genes that play a role in aging and then we can design drugs to mimic their actions."

While longevity genes may protect centenarians from bad habits, healthy lifestyle choices remain critical for the vast majority of the population. The U.S. Census Bureau estimates there were nearly 425,000 people aged 95 and older living in the U.S. in 2010 − a fraction (.01) of the 40 million U.S. adults 65 and over.

"Although this study demonstrates that centenarians can be obese, smoke and avoid exercise, those lifestyle habits are not good choices for most of us who do not have a family history of longevity," said Dr. Barzilai. "We should watch our weight, avoid smoking and be sure to exercise, since these activities have been shown to have great health benefits for the general population, including a longer lifespan."

References:

Newman, Kimberly. "Lifestyles of the Old and Healthy Defy Expectations." EurkAlert! AAAS, the Science Society, 3 Aug. 2011. Web. 4 Aug. 2011.
http://www.eurekalert.org/pub_releases/2011-08/aeco-lot072811.php.